Free Trial
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Sonoma Pharmaceuticals logo
$2.70
-0.09 (-3.23%)
(As of 12:38 PM ET)

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Key Stats

Today's Range
$2.70
$2.82
50-Day Range
$0.16
$5.20
52-Week Range
$2.32
$9.37
Volume
2,487 shs
Average Volume
160,137 shs
Market Capitalization
$2.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
12th Percentile Overall Score

SNOA MarketRank™: 

Sonoma Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Sonoma Pharmaceuticals are expected to grow in the coming year, from ($4.00) to ($1.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sonoma Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sonoma Pharmaceuticals is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sonoma Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sonoma Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.05% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently decreased by 24.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sonoma Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Sonoma Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.05% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently decreased by 24.98%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Sonoma Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

  • Read more about Sonoma Pharmaceuticals' insider trading history.
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

Rigged election?
Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late.
Sonoma Pharmaceuticals Inc (O8Z3.MU)
See More Headlines

SNOA Stock Analysis - Frequently Asked Questions

Sonoma Pharmaceuticals' stock was trading at $0.1804 on January 1st, 2024. Since then, SNOA stock has increased by 1,396.7% and is now trading at $2.70.
View the best growth stocks for 2024 here
.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. The business had revenue of $3.39 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 35.91% and a negative trailing twelve-month return on equity of 65.66%.

Sonoma Pharmaceuticals' top institutional investors include Ground Swell Capital LLC (1.08%).
View institutional ownership trends
.

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL).

Company Calendar

Last Earnings
8/08/2024
Today
11/04/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNOA
Employees
180
Year Founded
1999

Profitability

Net Income
$-4,840,000.00
Pretax Margin
-36.04%

Debt

Sales & Book Value

Annual Sales
$12.73 million
Book Value
$7.86 per share

Miscellaneous

Free Float
920,000
Market Cap
$2.68 million
Optionable
Not Optionable
Beta
1.38

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:SNOA) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners